PharmacoEconomics

Should Financial Incentives be Used to Differentially Reward `Me-Too' and Innovative Drugs?
pp. 1-17(17)
Author: Pekarsky, Brita

Adverse Drug Interactions: Moving from Perception to Action
pp. 19-22(4)
Authors: Mayhew, Ryan; McKoy, June M.; >Thanh Ha Luu,; Lopez, Isaac; Frick, Melissa; Bennett, Charles L.

The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients
pp. 23-34(12)
Authors: Hellinger, Fred J.; Encinosa, William E.

Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma: Long-Term Economic Evaluation
pp. 35-46(12)
Authors: Deconinck, Eric; Miadi-Fargier, Houda; >Claude Le Pen,; Brice, Pauline

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
pp. 47-60(14)
Authors: Rosen, Virginia M.; Taylor, Douglas C.A.; Parekh, Hemangi; Pandya, Ankur; Thompson, David; Kuznik, Andreas; Waters, David D.; Drummond, Michael; Weinstein, Milton C.

A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
pp. 61-74(14)
Authors: Meckley, Lisa M.; Gudgeon, James M.; Anderson, Jeffrey L.; Williams, Marc S.; Veenstra, David L.

Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer
pp. 75-92(18)
Author: Lyseng-Williamson, Katherine A.